Haemonetics Appoints David J. Wilson Plasma Business Unit President

News provided by

Sep 14, 2017, 08:00 ET

BRAINTREE, Mass., Sept. 14, 2017 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced the appointment of David J. Wilson as President, Plasma Business Unit, effective September 18, 2017.

Mr. Wilson is a proven business leader with over 20 years of experience in senior leadership roles at medical technology companies. Prior to joining Haemonetics, he was most recently President, Cordis (a Cardinal Health company), which he led from March 2015 through August 2017. Prior to Cordis, Mr. Wilson held positions of increasing responsibility at Johnson & Johnson driving sales, marketing, research and development, operations and business development. He earned a Bachelor of Mechanical Engineering from Auburn University, a Master's of Science in Biomedical Engineering from the University of Alabama at Birmingham, and an MBA from Columbia University.

Chris Simon, Haemonetics' CEO, stated: "David's strong leadership skills, diverse industry experience and proven results as a general manager make him the right person to execute the next phase of our Plasma business strategy. In the near term, he will oversee the launch of our NexSys PCS™ plasma collection system ensuring executional excellence. In addition, David will lead the Plasma team as it pursues further developments to its global product portfolio and business growth acceleration."

The Company previously issued guidance for fiscal 2018 revenue growth for its commercial Plasma business of 3-5%. The Company also indicated, at its June Investor Day event, a general rollout timeline for NexSys PCS, expectations for Plasma revenue growth over the next several fiscal years, and aspirational Company performance targets. Such guidance, indications and targets are reaffirmed and the Company noted that plans for the commercial launch of its NexSys PCS and related software are fully on track and proceeding as planned.

About Haemonetics

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative hematology products and solutions for our customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit our web site at http://www.haemonetics.com.

FORWARD LOOKING STATEMENTS

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements in this press release may include, without limitation, statements regarding plans and objectives of management for operations of the Company, including plans for commercialization of, and regulatory clearances related to, the Company's NexSys PSC plasma collection system and NexLynk DMS donor management system.

Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties.

Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, technological advances in the medical field and standards for transfusion medicine and our ability to successfully offer products that incorporate such advances and standards, product quality, market acceptance, regulatory uncertainties, including in the receipt or timing of regulatory clearances, the effect of economic and political conditions, the impact of competitive products and pricing, blood product reimbursement policies and practices, and the effect of industry consolidation as seen in the plasma market.

Additional risk factors are identified and described in more detail in the Company's filings with the SEC.

The Company does not undertake to update these forward-looking statements.

CONTACT:
Gerry Gould, VP-Investor Relations
(781) 356-9402
[email protected]

SOURCE Haemonetics Corporation